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Photoacoustic in vivo 3D 
imaging of tumor using 
a highly tumor‑targeting probe 
under high‑threshold conditions
Hisatsugu Yamada1,3*, Natsuki Matsumoto1, Takanori Komaki1, Hiroaki Konishi1, 
Yu Kimura1, Aoi Son1, Hirohiko Imai2, Tetsuya Matsuda2, Yasuhiro Aoyama1* & 
Teruyuki Kondo1*
Three‑dimensional (3D) representation of a tumor with respect to its size, shape, location, and 
boundaries is still a challenge in photoacoustic (PA) imaging using artificial contrast agents as probes. 
We carried out PA imaging of tumors in mice using 800RS‑PMPC, which was obtained by coupling 
of 800RS, a near‑infrared cyanine dye, with PMPC, a highly selective tumor‑targeting methacrylate 
polymer having phosphorylcholine side chains, as a probe. The conjugate 800RS‑PMPC forms compact 
nanoparticles (dDLS = 14.3 nm), retains the biocompatibility of the parent polymer (PMPC) and exhibits 
unprecedented PA performance. When applied to mice bearing a 6 × 3 × 3  mm3 tumor buried 6 mm 
beneath the skin, the probe 800RS‑PMPC selectively accumulates in the tumor and emits PA signals 
that are strong enough to be unambiguously distinguished from noise signals of endogenous blood/
hemoglobin. The PA image thus obtained under high‑threshold conditions allows 3D characterization 
of the tumor in terms of its size, shape, location, and boundaries.
Photoacoustic (PA) imaging is a growing bioimaging modality in which light-to-heat conversion mediated by 
light absorbers results in thermoelastic expansion of the surrounding tissues to lead to the emission of ultrasonic 
 waves1,2. Compared with fluorescence, ultrasonic waves have some fascinating features, especially for analysis 
with respect to depth, i.e., it shows far less (2–3 orders of magnitude) scattering by body tissues to allow deeper 
(several centimeters) penetration and much higher (submillimeter) spatial  resolution3–6. Since hemoglobin is an 
ideally PA-relevant endogenous chromophore, PA imaging is particularly suited for high-resolution 3D (three-
dimensional) imaging of the vasculature of body tissues such as skin and implanted  tumors7–9. Another approach 
is to use genetic reporters such as fluorescent proteins and pigments as "semi-endogenous" contrast  agents10,11. 
3D imaging of tumors formed of cells that have been lentivirally transduced to express a reporter protein is a 
notable recent  example12.
In addition to endogenous and semi-endogenous chromophores, there is a wide range of exogenous or arti-
ficial contrast agents that are absorption-tunable in the near-infrared (NIR) region (700–900 nm) and modifi-
able, particularly with biocompatible  polymers13–18, so that their biofunctions, such as their circulation in blood, 
selectivity, and efficiency, can be improved. Recent attention has also been paid to contrast agents in the so-called 
second NIR (1000–1700 nm) window (NIR-II)  region19,20 and their  formulation21 to allow higher spatial resolu-
tion, deeper penetration, and lower interference by tissue substrates with minimal autofluorescence. Under these 
circumstances, PA imaging of tumors in animals has been intensely studied in recent years using various types of 
NIR and NIR-II21 contrast agents  (dyes22–24, quantum  dots25,  nanoparticles26–28, semi-conducting  polymers29, and 
so  on30,31) in a variety of formulations and with diverse targeting  strategies32. Hopefully, the tumors, even when 
they are small and buried deep in the body, can be three-dimensionally drawn by these probes. To the best of our 
knowledge, however, this potentiality has not yet been adequately demonstrated, and remains a challenge. This 
is not surprising since the selectivity and efficiency of tumor-targeting by artificial probes are generally low and 
it is by no means easy to unambiguously distinguish weak signals of the probe accumulated in the tumor from 
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those of blood hemoglobin. In addition, in view of decay of the incident light in the depth direction, there is no a 
priori guarantee that probe molecules distributed in the tumor three-dimensionally are equally photo-excitable.
In this work, we studied PA imaging of a 6 × 3 × 3  mm3 tumor buried 6 mm beneath the skin in mice. We paid 
particular attention to overcome the inherent hemoglobin problem by using a highly tumor-targeting polymer 
conjugate of the reporter dye to enhance the probe signals and by employing high-threshold conditions to com-
pletely suppress blood hemoglobin noise. We report here that the tumor can be three-dimensionally visualized 
in terms of its size, shape, location, and surface/boundaries by genuine probe signals that survive under these 
high-threshold conditions. To the best of our knowledge, this is the first example of probe-targeting, in vivo 3D 
PA imaging of a relatively small tumor in relatively deep tissue. The present technique represents a powerful new 
approach to both basic research and (pre)clinical studies of tumors.
Results and discussion
The PA probe used here is 800RS-PMPC (Fig. 1). PMPC, poly(2-methacryloyloxyethylphosphorylcholine)15–17, 
is highly biocompatible and selectively accumulated in tumor due to the EPR (Enhanced Permeability and 
Retention)  effect18, and 800RS is a hydrophilic near-infrared (NIR) cyanine dye. 800RS was used here after we 
surveyed the performance of various NIR cyanine dye conjugates including its indocyanine green (ICG) coun-
terpart. In general, ICG-conjugated polymer probes including ICG-PMPC, also prepared by our group, bound 
nonspecifically to bovine serum albumin (BSA), which resulted in unavoidable accumulation of ICG-conjugated 
polymer probes in the  liver13. The conjugate 800RS-PMPC with a molecular weight of 56–71 kDa was obtained 
in a yield of ~ 50% via succinimidyl coupling of the respective precursors (see Supplementary Information). 
Notable instability or cytotoxicity was not observed for 800RS-PMPC during cold storage for months or years, in 
its absorption spectra (λmax = 771 nm vs, λmax = 770 nm for 800RS, Supplementary Fig. S5) upon repeated scans, 
or by MTT assay (see Supplementary Information and Supplementary Fig. S7) with a cell viability of ~ 100% at 
concentrations (≤ 100 µM) relevant to in vivo studies.
DLS (Dynamic Light Scattering) indicated that 800RS-PMPC has a slightly negative surface (ζ) poten-
tial of − 10.2 ± 2.0 mV and forms compact nanoparticles with a hydrodynamic diameter (intensity-weighted) 
of dDLS = 14.3 ± 0.4 nm (Fig. 2a) in a similar manner as the unmodified parent polymer, i.e.,  NH2-PMPC 
(10.9 ± 0.4 nm). Bigger particles in the 200–300 nm region in Fig. 2a, i.e., in the intensity-weighted formulation 
(proportional to the sixth power of the diameter) are of only limited significance, since they vanish in the vol-
ume-weighted formulation (proportional to the third power of the diameter) (Fig. 2b). The TEM (Transmission 
Electron Microscopy) image of the conjugate (Fig. 2c) and the size distribution histogram (Fig. 2d) with a mean 
diameter of 15.8 ± 2.8 nm agree with the DLS size of 14.3 nm, in a similar manner as other PMPC-containing 
 nanoparticles33,34. 800RS-PMPC has been shown to be highly biocompatible by QCM (Quartz Crystal Micro-
balance) measurements using a BSA-immobilized sensor chip, which show that 800RS-PMPC has practically 
no affinity for BSA (see Supplementary Fig. S8); bovine serum albumin is the most abundant serum protein. On 
the other hand, ICG-PMPC formed giant aggregates, bound nonspecifically to BSA, and was less selective in 
tumor-targeting, possibly as a consequence of the relatively hydrophobic nature of the ICG moiety as compared 
with its hydrophilized analogue 800RS (see Supplementary Information for details). After confirming that the 
characteristics of the parent polymer PMPC that make it a good EPR tumor-targeter, i.e., compact  size35–37 and 
 biocompatibility38–40, are retained in the conjugate 800RS-PMPC (but not in the conjugate ICG-PMPC), we 
moved on to PA imaging of tumors in mice.
Figure 1.  The chemical structure of 800RS-PMPC.
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Small tumors were injected into mice by the careful intramuscular inoculation of colon 26 cells several mil-
limeters beneath the skin of the right leg. The growth of the tumor was monitored by 7 T MRI. After 5 days, the 
tumor, shown by a yellow arrow in the indistinct MRI image (Fig. 3), was found to be located ~ 6 mm beneath 
the skin, i.e., from the inoculation point P, and to have an ellipsoidal shape with major and minor axes of ~ 6 mm 
and ~ 3 mm, respectively, as shown by the coronal image, i.e., top view of the tumor-containing coronal slice 
(Fig. 3). The tumor could also be readily visualized by PA imaging when tumor-bearing mice were injected 
intravenously with 800RS-PMPC (2.0 µmol/kg = 40 nmol/20-g mouse); we did not observe acute toxicity in any 
of the animals. In PA imaging, the mouse was placed in the PA apparatus with the tumor site at the bottom and 
irradiated with a pulsed laser at 790 nm (see “Methods” for details) from below at 48 h after the administration of 
800RS-PMPC. PA signals generated were collected by a 3D detector to produce 3D images. An actual PA image 
taken at an arbitrary high sensitivity with a scale of 0–1600 is shown in Fig. 4a. It is composed of several bright 
areas in addition to a less intense background which is due to blood vessels containing PA-active hemoglobin, as 
independently confirmed. Blood (hemoglobin) signals may be conveniently removed by subtraction of the image 
in the absence of the probe from that in its presence. This subtraction method is often used in the  literature30,31. 
However, care should be taken when interpreting less-intense signals that survive subtraction because they 
can still be noise. An alternative and more persuasive/convincing approach, if possible, would be to consider 
a
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Figure 2.  Intensity-weighted (a) and volume-weighted (b) DLS (Dynamic Light Scattering) size distribution 
profiles and TEM (Transmission Electron Microscopic) images (c) and size distribution histogram (d) for 
800RS-PMPC. DLS samples of 800RS-PMPC (1 mg/mL  H2O) were filtered through a 0.8 µm filter just prior to 
measurements. TEM samples of 800RS-PMPC (2 mg/mL  H2O) were negatively stained with phosphotungstic 
acid (2.8 wt%, pH 7.0).
Figure 3.  MR (Magnetic Resonance) images (axial and coronal) at 7 T for a tumor-bearing mouse 5 days after 
inoculation of colon 26. The tumor is marked with a yellow arrow.
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only doubtless probe signals that are more intense than even the most intense endogenous signals. Under these 
hemoglobin-suppressing, low-sensitivity, or high-threshold conditions with a scale of 1200–1600 (see “Methods” 
for details), a tumor-bearing mouse treated with 800RS-PMPC exhibited a clear PA image (Figs. 4b and 5 with 
(4b) or without (5) a merged bright-field image) composed of at least four bright spots/areas (A, B, C, and D in 
the top-left panel of Fig. 5), in marked contrast to the no-signal image for a tumor-bearing but 800RS-PMPC-
nontreated reference mouse under otherwise identical conditions (Fig. 4c). Splitting of bright or hot spots was 
observed repeatedly (n = 3) for 800RS-PMPC-administered mice (see Supplementary Fig. S9b as another exam-
ple), but was not clear when ICG-PMPC as a control was used in place of 800RS-PMPC (Supplementary Fig. S9a).  
With reference to the horizontal (x), longitudinal (y), and vertical (z) coordinates illustrated in Fig. 4d, the 
PA image in Fig. 4b is actually the projection of the 3D image on the xz plane and the vertical distance (along 
the laser path) from point P (the inoculation point on the skin) represents depth. Thus, referring to Fig. 4b, the 
shallow three bright spots (B, C, and D in the top-left panel of Fig. 5) are embedded inside the mouse body with 
a depth (from point P) of lBCD =  ~ 5 mm and the fourth spot (A) is buried deeper (lA =  ~ 8 mm) and is less bright. 
The four bright spots as a whole are accommodated within a volume centered at ~ 6 mm deep from the skin and 
with a thickness of lth =  ~ 3 mm and an apparent xy or horizontal/longitudinal width of lxy =  ~ 4 mm. Assuming 
that the PA signals come from the probe, i.e., 800RS-PMPC, its distribution in the xy (horizontal/longitudinal) 
plane becomes clearer if we rotate the viewpoint around the z (laser path) axis, referring to Fig. 4d. The PA images 
at tilt angles of 0°, 45°, 90°, 135°, 180°, 225°, 270°, and 315° are shown in Fig. 5 (see Supplementary Information 
for a movie). During rotation, the thickness (lth) of the volume that encompasses the four bright spots remains 
constant at ~ 3 mm, as expected. On the other hand, the apparent xy (horizontal/longitudinal) width (lxy) of the 
four bright spots overall changes with changes in the tilt angles and is shortest (3 mm) at 135° and 315°, longest 
(6 mm) at 45° and 225°, and intermediate at 90° and 180° (Fig. 5). These results leave little doubt that the four 
bright spots are contained within the same volume (see the drawings in Fig. 5), which has an ellipsoidal shape 
with a major axis of 6 mm, a minor axis of 3 mm, and a thickness of 3 mm and is centered at ~ 6 mm from the 
skin. The location, shape, and size of this ellipse are in excellent agreement with those of the MRI-visualized 
tumor (~ 6 mm × ~ 3 mm, centered at ~ 6 mm from the skin, referring to Fig. 3). We are thus led to conclude that 
the PA signals obtained under the hemoglobin-suppressing, low-sensitivity, or high-threshold conditions come 
from the probe 800RS-PMPC distributed not only on the front surface (B, C, and D) but also on the rear surface 
(A) of the tumor, and thereby they define the surface or boundary and, as a consequence, allow us to draw a 3D 
image of the tumor to the same extent as MRI visualization of the tumor. While the non-uniform distribution of 
the intense PA signals of the probe on the tumor surface is not readily explainable, it is by no means surprising 
since there is no reason to expect that new blood vessels from which the probe leaks into the tumor by the EPR 
effect should be uniformly formed at the tumor site. Nevertheless, the present work raises the question of the 
apparent localization of the probe on the surface and not inside of the tumor. To answer this question, we need 
to know more not only about the intra-tumor trafficking of this type of polymeric probe, but also about the 
























Figure 4.  PA (Photoacoustic) images for a tumor-bearing and 800RS-PMPC-administered (2.0 µmol/
kg = 40 nmol/20-g mouse) mouse under ambient high-sensitivity conditions with a sensitivity scale of 0–1600 
(a), for a tumor-bearing and 800RS-PMPC-administered mouse as in (a) but under hemoglobin-suppressing, 
low-sensitivity, or high-threshold conditions with a sensitivity scale of 1200–1600 (b), and for a tumor-
bearing mouse without administration of 800RS-PMPC under hemoglobin-suppressing, low-sensitivity, or 
high-threshold conditions (c) as in (b). The PA image in (b) is merged with a bright-field image. (d) shows a 
schematic representation of coordinate axes illustrating the arrangement of the object (tumor-bearing mouse) 
and the direction of the incident laser pulse.
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Conclusions
In summary, this study demonstrated that high-quality, MRI-consistent, and much clearer 3D anatomical images 
of a 6 × 3 × 3  mm3 tumor buried 6 mm beneath the skin were obtained by probe-targeting in vivo PA imaging. 
This method may provide a powerful new approach to 3D monitoring of the morphological changes of tumors 
associated with, for example, their development/growth and response to therapy. Clinically, a critical issue in 
tumor surgery is tumor thickness. The present tool may illustrate a PA approach to the operative or intraopera-
tive monitoring of a tumor to be removed.
A methodological advantage or innovation of this work lies in the setting of a high threshold to completely 
suppress the hemoglobin noise signals. Independent PA imaging of deoxyhemoglobin (Hb) and oxyhemoglobin 
 (HbO2) in a blood vessel to measure the oxygen saturation of hemoglobin  (sO2) has been established within 
the last  decade1,2. However, PA signals of hemoglobin act as endogenous noise signals to obtain 3D PA images 
of the tumor surrounded by the probe. Accordingly, the PA signals of the probe accumulated in the tumor site 
must be strong enough to survive under hemoglobin-suppressing, high-threshold conditions, where the high 
tumor-targeting ability of the PMPC backbone of the probe, 800RS-PMPC, must play an important role. Indeed, 
ex vivo studies with fluorescence quantification showed that the 800RS-PMPC probe selectively accumulated 
in the tumor with an efficiency of 11.6% ID/g (ID = injected dose), as compared with 13% ID/g for the doubly 
13C/15N-labeled and self-traceable  PMPC18. However, this is not the whole story. It is also important that the 
incident laser light is not consumed at the front surface of the tumor, but rather passes through it to reach the 
rear surface to excite the probe there to give information about the rear surface. In this context, we have to shed 
more light on the photophysics of the probe and the site-dependency of the PA intensity thereof. While various 
contributing factors remain to be systematically analyzed, the present work opens the door to the sophisticated 
use of high-contrast in vivo PA imaging for tumor tomography and illustrates some key properties the probe 
should have for that purpose. Further work along these lines is now underway.
Figure 5.  Projections on the xz plane (referring to the coordinates shown in Fig. 4d) of the 3D PA image of a 
tumor-bearing and 800RS-PMPC-administered mouse at various angles with respect to rotation around z, i.e., 
incident laser axis. The drawings illustrate how four bright spots (A, B, C, and D) within an ellipse move upon 
rotation. Scale bars: 5 mm.
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Methods
General. NMR spectra were obtained on a Bruker Avance-500 (500 MHz) spectrometer with solvent peaks 
as references. GPC analyses were conducted at 40 °C on a JASCO LC-Net II/ADC system equipped with a Sho-
dex SB-803HQ column. An aqueous solution of  NaNO3 (0.1 M) with  NaN3 (0.2 wt%) was used as an eluent at a 
flow rate of 1.0 mL/min. Absorption spectra were recorded using a HITACHI U-3010 UV/Vis spectrophotom-
eter equipped with a Peltier device (EHC-573T). Dynamic Light Scattering (DLS) and ζ potential measurements 
were performed for aqueous solutions (1 mg/mL) of PMPC samples on a Malvern Zetasizer Nano-ZS analyzer 
(equipped with a ZEN 9062 filter) with a 4 mW He–Ne laser at 633 nm. Transmission Electron Microscopy 
(TEM) images were obtained with a JEOL JEM-1400 microscope at an acceleration voltage of 100 kV. A solution 
(2 mg/mL) of PMPC samples in water was dispersed onto hydrophilic copper grids, and excess solution was 
removed with filter paper. The grids were immersed in phosphotungstic acid (2.8 wt%, pH 7.0) as a negative 
staining agent, and then subjected to TEM measurements. The TEM images were analyzed using ImageJ soft-
ware to give size distribution histograms. Photoacoustic (PA) imaging was conducted with an Endra Nexus 128 
preclinical photoacoustic computed tomography scanner, and the PA images were reconstructed and analyzed 
using OsiriX software (Newton Graphics) according to the manufacturer’s instructions. 1H MR images of mice 
were obtained using a Bruker 7T MR system (Biospec 70/20 USR) as described  elsewhere18.
Preparation and properties of 800RS‑PMPC and ICG‑PMPC. 800RS-PMPC was obtained as shown 
in Supplementary Scheme S1. The number average molecular weights (Mn) of 800RS-PMPC conjugates were 
estimated from the ratios of NMR integration for the methylene protons of the repeating MPC units in the 
PMPC polymer chain to that for the aromatic protons in the dye moiety at the terminus of the conjugates. Poly-
dispersity indices (Mw/Mn) were evaluated from GPC profiles calibrated with poly(ethylene glycol) standards.
Fmoc‑PMPC. Fmoc-PMPC was obtained by ATRP (Atom Transfer Radical Polymerization) of 2-methacry-
loyloxyethylphosphorylcholine (MPC) using Fmoc-protected bromoisobutylate derivative (Fmoc-initiator)41 as 
an initiator under manipulated control of the initiator/monomer ratios. Thus, in a typical preparation, CuBr 
(2.9 mg, 0.020 mmol) and 2,2′-bipyridine (6.16 mg, 0.039 mmol) as catalysts were added to a solution of MPC 
(511.6 mg, 1.73 mmol) and Fmoc-protected initiator (5.8 mg, 0.010 mmol) in degassed methanol (1.0 mL) in a 
nitrogen glove box. The mixture was stirred at room temperature for 4 days. When the reaction was complete, 
the solution was passed through a thin silica gel layer with methanol as an eluent. The eluate was concentrated, 
and anhydrous methanol and THF were added to the residue. The polymeric product that precipitated was col-
lected, washed with anhydrous THF, dried under reduced pressure, purified by ultrafiltration using a centrifugal 
filter with a cut-off molecular weight of 10 kDa, and lyophilized to give Fmoc-PMPC as a white powder in a 
yield of 63%; 1H NMR (500 MHz,  CD3OD) δ: 7.83 (d, 2H, J = 7.3 Hz), 7.67 (d, 2H, J = 6.6 Hz), 7.37–7.45 (m, 2H), 
7.30–7.37 (m, 2H), 4.28–4.40 (br m, ~ 400H), 4.14–4.28 (br m, ~ 280H), 3.98–4.14 (br m, ~ 350H), 3.67–3.77 (br 
m, ~ 390H), 3.22–3.33 (br m), 1.40–2.30 (br m, ~ 360H), 0.70–1.26 (br m, ~ 580H).
NH2‑PMPC. A solution of Fmoc-PMPC (149.8 mg, 2.7 µmol) and DBU (20.5 µL, 0.14 mmol) in methanol 
(1.0 mL) was stirred for 3 h at room temperature. The progress of the reaction was checked by ninhydrin colorim-
etry. The solution was concentrated, and the residue was reprecipitated with anhydrous methanol and THF. The 
precipitate was collected and dried under reduced pressure to give deprotected  NH2-PMPC as a white powder in 
a quantitative yield; 1H NMR (500 MHz,  D2O) δ: 4.22–4.31 (br m, ~ 420H), 4.10–4.22 (br m, ~ 350H), 3.95–4.10 
(br m, ~ 380H), 3.61–3.68 (br m, ~ 390H), 3.16–3.27 (br m, ~ 1850H), 1.50–2.15 (br m, ~ 400H), 0.63–1.20 (br 
m, ~ 600H). The absence of the characteristic signals for the 9-fluorenyl group of Fmoc at 7.83, 7.67, 7.37–7.45, 
and 7.30–7.37 in the  NH2-PMPC product confirmed complete deprotection of the precursor Fmoc-PMPC.
800RS‑PMPC. 800RS-PMPC was obtained by the coupling of  NH2-PMPC and the corresponding 
N-hydroxysuccinimidyl (NHS) ester of 800RS, i.e., IRDye 800RS NHS ester (800RS-NHS; Li-Cor). A typical 
procedure is as follows.  NH2-PMPC (Mn = 54,000) (0.57 µmol) and 800RS-NHS (1.03 µmol) were dissolved in 
anhydrous methanol and the mixture was stirred for 44–48 h at room temperature in the dark. The solution was 
ultrafiltrated using a centrifugal filter unit with a cut-off molecular weight of 10 kDa, and further purified with 
a Sephadex G25 column (PD-10, GE Healthcare) to give 800RS-PMPC (Mn = 56,000, Mw/Mn = 1.66) in a yield of 
54%; 1H NMR  (CD3OD, 500 MHz) δ: 7.88 (d, 1H, J = 13.7 Hz), 7.82 (d, 1H, J = 14.2 Hz), 7.73–7.78 (m, 2H), 7.20–
7.33 (m, 5H), 7.04–7.17 (m, 5H), 6.16 (d, 1H, J = 14.1 Hz), 6.04 (d, 1H, J = 14.8 Hz), 4.18–4.29 (br m, ~ 360H), 
4.04–4.18 (br m, ~ 250H), 3.88–4.04 (br m, ~ 330H), 3.60–3.70 (br m, ~ 380H), 3.22–3.33 (br m), 1.30–2.30 (br 
m, ~ 360H), 0.60–1.16 (br m, ~ 560H); absorption and fluorescence maxima (2 µM in  H2O) 771 nm and 788 nm 
(excitation at 771 nm), respectively.
ICG‑PMPC. The indocyanine green conjugate of PMPC (ICG-PMPC) was obtained in a yield of 70% in a 
similar manner as 800RS-PMPC, i.e., by coupling of  NH2-PMPC and the corresponding N-hydroxysulfosuc-
cinimidyl ester of ICG (ICG-Sulfo-OSu; Dojindo). (Mn = 56,000, Mw/Mn = 1.28); 1H NMR  (CD3OD, 500 MHz) 
δ: 8.19–8.26 (m, 2H), 7.95–8.08 (m, 6H), 7.44–7.67 (m, 7H), 6.55–6.67 (m, 2H), 6.27–6.46 (m, 2H), 4.28–4.40 
(br m, ~ 380H), 4.14–4.28 (br m, ~ 280H), 3.97–4.14 (br m, ~ 340H), 3.67–3.77 (br m, ~ 380H), 3.22–3.33 (br m), 
1.40–2.30 (br m, ~ 380H), 0.70–1.26 (br m, ~ 550H); absorption and fluorescence maxima (2 µM in  H2O) 786 nm 
and 805 nm (excitation at 786 nm), respectively.
The 1H NMR spectra for Fmoc-PMPC,  NH2-PMPC, 800RS-PMPC, and ICG-PMPC, and the absorption 
spectra for 800RS-PMPC and 800RS are shown in Supplementary Figs. S1–S5.
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Cell culture. The mouse colon carcinoma cell line (Colon 26) and the mouse fibroblasts (L929) were sup-
plied by Prof. Yasuhiko Tabata (Kyoto University, Japan) and maintained in 10% FBS-RPMI1640 medium and 
10% FBS-D-MEM medium, respectively. Cells were incubated in a well-humidified incubator with 5%  CO2 and 
95% air at 37 °C.
MTT assay of the cytotoxicity of 800RS‑PMPC. The cytotoxicity of 800RS-PMPC was evaluated 
(n = 5) by MTT assay at 0.01–100  µM. This concentration range covers the blood level of 800RS-PMPC in 
in vivo studies, where the dose of 800RS-PMPC (40 nmol/20-g mouse) corresponds to a blood level of [800RS-
PMPC] = 20 µM (assuming that the volume of the blood of a mouse is ~ 2 mL). Cells (L929 mouse fibroblasts) 
were seeded at a density of 1.0 × 104 cells/cm2 in a 96-well plate and cultivated. After 24 h, the medium was 
replaced by a fresh medium containing 800RS-PMPC, and the cells were incubated for 48 h at 37  °C. After 
removal of the medium, the cells were washed with PBS three times and subjected to MTT assay for viable cells.
Ethics of animal experiments. All animal experiments using BALB/cSlc-nu/nu mice (6-week-old, 
female, Japan SLC Inc.) were approved by the animal experiment committee of the Faculty of Engineering and 
Radioisotope Research Center at Kyoto University, and performed according to the Institutional Guidelines of 
Kyoto University. At the end of the experiments, the mice were sacrificed by an overdose of sodium pentobarbi-
tal. The tissues were rapidly removed, frozen in liquid nitrogen and stored at − 80 °C.
QCM analysis of the interaction of 800RS‑PMPC and ICG‑PMPC with BSA. A quartz crystal 
microbalance (QCM) analysis was performed on an AFFNIX-Q QCM system. A solution of 800RS-PMPC or 
ICG-PMPC (500 molar equivalents of immobilized BSA) in PBS buffer was slowly added to the quartz crystal 
sensor immobilizing BSA (159 ~ 338 fmol). Changes in frequency (ΔF), normalized to the initial changes (ΔFBSA) 
upon immobilization of BSA, were recorded on the QCM system until adsorption was saturated (see Supple-
mentary Fig. S8).
Photoacoustic imaging of tumor‑bearing mice. Colon 26 cells (2 × 105 cells) suspended in a 50% Gel-
trex-PBS solution (3 µL) were injected intramuscularly into the right leg of female BALB/cSlc-nu/nu mice. MR 
images of the mice 5 days after inoculation showed that the tumor had developed in deep tissue and were of an 
appropriate size. Next, the mice were administered 800RS-PMPC (40 nmol in 200 µL of saline) intravenously 
via the tail vein, set in the PA apparatus, and irradiated from below with a laser pulse (790 nm) at 48 h after the 
administration of 800RS-PMPC. We selected the excitation wavelength of 790 nm, which was shifted toward a 
longer wavelength by ~ 20 nm from the absorption maximum (771 nm) of 800RS-PMPC, to reduce the contri-
bution of hemoglobin (deoxyhemoglobin) which still shows significant absorption in this region (770–800 nm) 
with decreasing absorbance at longer wavelengths. PA images were acquired using the following acquisition 
parameters: number of angles = 120, number of pulses per angle = 20, laser intensity = 7.2–7.6 mJ, and the vol-
ume of interest = 25 × 25 × 25  mm3. PA images (2D/3D) and 3D movie data (Supplementary Movie) were recon-
structed using OsiriX software and by manipulating the window level (WL), corresponding to brightness, and 
window width (WW), corresponding to contrast. Setting these at WL = 800 and WW = 1600 to give a sensitivity 
scale of 0–1600 represents high-sensitivity conditions (Fig. 4a). Setting these at WL = 1400 and WW = 400 to give 
a scale of 1200–1600 represents low-sensitivity or high-threshold conditions (Figs. 4b,c, 5, and Supplementary 
Movie). The body temperature of the mice was maintained by using a water-heating system at 38 °C. During the 
measurement, the mouse was under anesthesia with 1–2% isoflurane in air.
Ex vivo fluorescence imaging of tumor‑bearing mice treated with 800RS‑PMPC and 
ICG‑PMPC. Female BALB/cSlc-nu/nu mice at 6 weeks of age were inoculated subcutaneously with a 50% 
Geltrex-PBS solution (50 µL) of 1 × 106 cells of the cell line colon 26 at the right shoulder 7–8 days prior to the 
experiments. A tumor-bearing mouse weighing ~ 20 g was injected intravenously, under anesthesia with 1–2% 
isoflurane in air, with a PBS solution (200 µL) of 800RS-PMPC or ICG-PMPC (1.0 µmol/kg = 20 nmol/mouse) 
via the tail vein. The mouse was sacrificed by an overdose of sodium pentobarbital 48 h after administration of 
the probe. Tissues (tumor, liver, kidney, heart, and spleen) were collected and weighed. The fluorescence images 
(see Supplementary Fig. S10) were obtained using an IVIS Spectrum (Xenogen) in vivo imaging system, and the 
images were analyzed using Living Image 4.3.1 software (Xenogen) according to the manufacturer’s instructions.
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